Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosinkinases

Abstract

Aim. To analyse clinical implications of chromosome 8 trisomy in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia (CML) treated with inhibitors of tyrosinkinases (ITK).
Material and methods. A total of 386 patients with CML (chronic phase - 288, acceleration phase - 77) received imatinib (400-800 mg/day). Because of resistance and/or intolerance some patients were switched to ITK II (nilotinib, dasatinib, bozutinib). This study included 8 CML patients (7 in a chronic phase, 1 in acceleration phase) treated with BCR-ABL ITK inhibitors of the first (imatinib) and the second line (ITK-II). The standard cytogenetic examination, on demand - investigation of the interphase nuclei with FISH, in some cases morphological, cytochemical and histological examinations of the bone marrow were made.
Results. The existence of a Ph-negative clone with trisomy of chromosome 8 had no negative effect on the course of the disease. The patients showed a stable hematological and cytogenetic response and no need in changing treatment policy. In long-term follow-up Ph-negative clone with trisomy of the chromosome 8 persisted without a clear trend to rise in most patients.
Conclusion. Detection of a Ph-negative clone with chromosome 8 trisomy at early stages suggests parallel existence of Ph-positive and Ph-negative clones. None of the patients had myelodisplasia.

References

  1. Nowell P. C., Hungerford D. A. Chromosome studies on normall and leukemic human leukocytes. J. Natl. Cancer Inst. 1960; 25: 85-109.
  2. Rowley J. D. A new consistent chromosomal abnomality in chronic myelogenous leukemia giemsa starting. Nature 1973; 243: 290-303.
  3. Fialkow P. J., Jacobson R. J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am. J. Med. 1997; 63: 125-130.
  4. Gordon M. Y. Cellular and molecular mechanisms in chronic myeloid leukemia: biology and treatment. Br. J. Haematol. 1996; 95: 10-20.
  5. Домрачева Е. В., Захарова Е. А., Асеева Е. А. Прогностическое значение дополнительных цитогенетических аномалий при хроническом миелолейкозе. Гематол. и трансфузиол. 2005; 50 (4): 37-41.
  6. Мартынкевич И. С., Мартыненко Л. С., Иванова М. П. и др. Дополнительные хромосомные аберрации у больных хроническим миелолейкозом. Гематол. и трансфузиол. 2007; 52 (2): 28-35.
  7. Guilhot F., Chastang C., Michallet M. et al. For the French CML Study Group. Interferon alfa-2b combined with cytarabin versus interferon along in chronic myelogenous leukemia. N. Engl. J. Med. 1997; 337 (4): 223-229.
  8. Kantarjian H. M., Cortes J. E., O'Brien S. et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101: 97-100.
  9. Guilhot F. G., Roy L., Millot F. Update of first-line in chronic phase chronic myeloid leukemia. In: Hematology: Educational program of the 11 congress of EHA, Amsterdam, the Netherlands, June 15-18, 2006. Amsterdam; 2006: 93-97.
  10. O'Brien S. G., Guilhot F. G., Goldmann G. V. et al International randomized study interferon versus STI571(IRIS) 7-year follow up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 2008; 112: 76, abstr. 186.
  11. Jabbour E., Kantarjian H., Abruzzo L. Chromosomal abnomalites in Philadelphia Chromosome (Ph)-negative metaphases during novel tyrosine kinase inhibitors. Blood 2006; 108 (11): abstr. 2115, 600a.
  12. Haferlach C., Schnittger S., Fabarius A. Analysis of Philadelphia negative clones detected during treatment with tyrosine kinase inhibitors. A study on 63 CML cases. Blood 2007; ASH, abstr. 4541, 207B.
  13. Meeus P., Demuynck H., Martiat Ph. et al. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib. Leukemia 2003; 17: 465-467.
  14. Deininger M. N. Chronic myeloid leukemia. Management of early stage disease. Hematol. Am. Soc Hematol., 2005: 174-182.
  15. Туркина А. Г., Хорошко Н. Д., Дружкова Г. А. и др. Эффективность терапии иматиниб мезилатом (гливеком) в хронической фазе миелолейкоза. Тер. арх. 2003; 8: 23-25.
  16. Козинец Г. И., Дульцина С. М., Герасимова Н. А., Дягилева О. А. Цитохимическая характеристика гемопоэтических клеток здоровых людей: Метод. рекомендации. М.; 1980: 33-35.
  17. Stephen G., Francois G., Richard A. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic - phase chronic myeloid leukemia. N. Engl J. Med. 2003; 348: 994-1004.
  18. Schoch C., Haferlach T., Kernn W. et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003; 17: 461-463.
  19. Nguyen P., Arthur D. C., Litz C. E. et al. Fluorescence in situ hybridization (FISH) detection of trisomy 8 in myeloid cells in chronic myeloid leukemia (CML): a study of archival blood and bone marrow smears. Leukemia 1994; 8: 1654-1662.
  20. Кишева Л. П. Дизэритропоэз при лейкозах: Автореф. дис. ... канд. мед. наук. М.; 1982.
  21. Виноградова О. Ю. Изменения метаболизма железа как показателя неэффективного эритропоэза при трансфузионно-зависимых рефрактерных анемиях: Автореф. дис. ... канд. мед. наук. М.; 1999.

Statistics

Views

Abstract: 92

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Turkina A.G., Domracheva E.V., Vorontsova A.V., Aseeva E.A., Vinogradova O.Y., Stakhina O.V., Gusarova G.A., Dyagileva O.A., Semenova E.A., Vakhrusheva M.V., Kolosheynova T.I., Abakumov E.M., Chelysheva E.Y., Goryacheva S.R., Ivanova T.V., Zakharova E.S., Kolosova L.Y., Zakharova A.V., Naumova I.N., Dyachenko L.V., Kulikov S.M., Kovaleva L.G., Khoroshko N.D., Turkina A.G., Domracheva E.V., Vorontsova A.V., Aseeva E.A., Vinogradova O.Y., Stakhina O.V., Gusarova G.A., Dyagileva O.A., Semenova E.A., Vakhrusheva M.V., Kolosheinova T.I., Abakumov E.M., Chelysheva E.Y., Goryacheva S.R., Ivanova T.V., Zakharova E.S., Kolosova L.Y., Zakharova A.V., Naumova I.N., Dyachenko L.V., Kulikov S.M., Kovaleva L.G., Khoroshko N.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies